Bio Patent Investment Firm Approaches 52-Week High, Executive Sells Portion of Shares

Terence P. Coyne, Chief Financial Officer and Vice President of U.S. biotech patent investment firm Royalty Pharma plc (NASDAQ: RPRX), sold approximately 34,000 shares of the company’s Class A common stock on April 28 under a pre-established Rule 10b5-1 trading plan. The shares were disposed of at about $49.78 each, generating roughly $1.73 million in proceeds—equivalent to the mid-2 billion-won range. Coyne continues to hold a substantial direct and indirect stake through personal and family accounts and exercisable equity.

On May 5, Royalty Pharma’s shares reached a 52-week high of around $50.50 on the New York Stock Exchange, pushing its market capitalization to about $30 billion (approximately 40 trillion won). In mid-April, the board approved a second-quarter dividend of $0.235 per share (roughly 300 won).

Founded in 1996 and headquartered in New York, Royalty Pharma is the world’s largest pharmaceutical royalty investment company. It provides non-dilutive capital to biotech and pharmaceutical firms by acquiring drug patent royalties and milestone revenue rights.